# Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome

> **NCT03274973** · — · TERMINATED · sponsor: **Ferring Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Growth Disorders

## Interventions

- **DRUG:** Zomacton

## Key facts

- **NCT ID:** NCT03274973
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-14
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Insufficient, delayed recruitment of participants
- **Last updated:** 2018-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274973, "Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03274973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*